XML 38 R31.htm IDEA: XBRL DOCUMENT v3.25.3
Restatement of Previously Issued Financial Statements (Tables)
9 Months Ended
Sep. 30, 2025
Accounting Changes and Error Corrections [Abstract]  
Schedule of Impact of Correction Misstatements

The impact of the correction of the misstatements is summarized below (in thousands):

 

 

As of
September 30, 2024

 

 

 

As Previously Reported

 

 

Restatement Impact

 

 

As Restated

 

 

 

 

 

 

 

 

 

 

 

LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Convertible preferred stock, 5,000,000 shares authorized at September 30, 2024 and December 31, 2023:

 

 

 

 

 

 

 

 

 

Series X1 non-voting convertible preferred stock, $0.001 par value, 515,000 shares designated; 110,086 shares issued and outstanding at September 30, 2024 and December 31, 2023

 

$

 

 

$

53,543

 

 

$

53,543

 

Series X non-voting convertible preferred stock, $0.001 par value, 10,000 shares designated; 4,422 shares issued and outstanding at September 30, 2024 and December 31, 2023

 

 

 

 

 

2,151

 

 

 

2,151

 

 

 

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

 

Convertible preferred stock, 5,000,000 shares authorized at September 30, 2024 and December 31, 2023:

 

 

 

 

 

 

 

 

 

Series X1 non-voting convertible preferred stock, $0.001 par value, 515,000 shares designated; 110,086 shares issued and outstanding at September 30, 2024 and December 31, 2023

 

 

 

 

 

 

 

 

 

Series X non-voting convertible preferred stock, $0.001 par value, 10,000 shares designated; 4,422 shares issued and outstanding at September 30, 2024 and December 31, 2023

 

 

 

 

 

 

 

 

 

Additional paid-in capital

 

 

386,884

 

 

 

(55,694

)

 

 

331,190

 

Total stockholders’ equity

 

$

76,058

 

 

$

(55,694

)

 

$

20,364

 

 

 

For the Three Months
Ended September 30, 2024

 

 

For the Nine Months
Ended September 30, 2024

 

(In thousands, except share and per share data)

 

As Previously Reported

 

 

As Restated

 

 

As Previously Reported

 

 

As Restated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss attributable to common shares - diluted

 

$

(17,504

)

 

$

(15,703

)

 

$

(61,086

)

 

$

(53,230

)

Diluted earnings per share of common stock

 

$

(0.32

)

 

$

(0.28

)

 

$

(1.42

)

 

$

(1.23

)

Weighted-average number of shares outstanding - diluted

 

 

55,478,342

 

 

 

55,478,342

 

 

 

43,106,746

 

 

 

43,106,746

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income attributable to Series X and Series X1 non-voting convertible preferred stocks - basic

 

$

 

 

$

6,666

 

 

$

 

 

$

852

 

Basic earnings per share of Series X and Series X1 non-voting convertible preferred stock

 

$

 

 

$

58.21

 

 

$

 

 

$

7.44

 

Weighted-average shares outstanding of Series X and Series X1 non-voting convertible preferred stock, basic

 

 

 

 

 

114,508

 

 

 

 

 

 

114,508

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss attributable to Series X and Series X1 non-voting convertible preferred stocks - diluted

 

$

 

 

$

(1,801

)

 

$

 

 

$

(7,856

)

Diluted earnings per share of Series X and Series X1 non-voting convertible preferred stock

 

$

 

 

$

(15.73

)

 

$

 

 

$

(68.60

)

Weighted-average shares outstanding of Series X and Series X1 non-voting convertible preferred stock, diluted

 

 

 

 

 

114,508

 

 

 

 

 

 

114,508